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ABSTRACT 
Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly and 
accounts for 60-80% of all cases of dementia. Currently, the diagnosis of AD is based on cognitive 
tests and mental state exams, but the peptide amyloid-beta (Aβ) in cerebrospinal fluid (CSF) is 
increasingly used in clinical trials and settings. As for most protein and peptide biomarkers, 
quantification is performed using antibody-based techniques such as enzyme-linked immunosorbent 
assay (ELISA). However these immunoassays suffer from high variability in measurements of Aβ 
concentrations, hampering its use as a diagnostic marker.  
 The aim of this thesis was to develop an antibody independent method for absolute 
quantification of Aβ in human CSF, free of the specificity and reproducibility issues associated with 
antibody-based quantification. The method was based on solid-phase extraction (SPE) and liquid 
chromatography (LC)-tandem mass spectrometry (MS/MS). Stable isotope labeled Aβ peptides were 
used as internal standards, enabling absolute quantification. The method was first tested in a pilot 
study with CSF samples from AD patients and controls. As expected, the level of the 42 amino acid 
variant of Aβ (Aβ1-42) was decreased in AD CSF as compared to controls (p<0.01). The results were 
similar to those obtained with conventional ELISA, and an even better separation between the groups 
was obtained when using the Aβ1-42/Aβ1-40 ratio. To investigate whether the antibody independent 
method would give similar results across different research centers, an inter-laboratory study was 
initiated which included three other laboratories using similar LC-MS/MS methods. Results showed 
good agreement and highlighted the importance of a certified reference material (CRM) to further 
increase the agreement between laboratories and MS methods. The method was further optimized, 
validated and published as a candidate reference measurement procedure (RMP). An RMP is required 
to set the value of a CRM used as a ‘gold standard’ to harmonize CSF Aβ measurements. To 
investigate if the large number of Aβ peptides in addition to Aβ1-38, Aβ1-40 and Aβ1-42 found in CSF 
could also be found in human plasma, an immunoprecipitation-based method for enrichment of Aβ 
peptides was developed. Sixteen N- or C-terminally truncated Aβ peptides were reproducibly detected 
using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS. While 
quantification of Aβ1-38, Aβ1-40 and Aβ1-42 using LC-MS/MS showed no AD association, the method 
may be useful in clinical trials of drugs affecting amyloid precursor protein (APP) processing or Aβ 
homeostasis.  
 In summary, absolute quantification of Aβ1-42 using the developed LC-MS-MS method 
overcomes many of the issues associated with antibody-based methods. The method is currently being 
considered for formal certification as a RMP to determine the absolute concentration of Aβ1-42 in a 
CRM to harmonize CSF Aβ1-42 measurements across techniques and analytical platforms. 
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